(NASDAQ: CNTA) Centessa Pharmaceuticals's forecast annual revenue growth rate of -61.41% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 109.19%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 26.12%.
Centessa Pharmaceuticals's revenue in 2025 is $15,000,000.On average, 17 Wall Street analysts forecast CNTA's revenue for 2025 to be $2,258,735,176, with the lowest CNTA revenue forecast at $1,970,879,509, and the highest CNTA revenue forecast at $4,674,336,273. On average, 15 Wall Street analysts forecast CNTA's revenue for 2026 to be $420,990,589, with the lowest CNTA revenue forecast at $0, and the highest CNTA revenue forecast at $4,767,785,458.
In 2027, CNTA is forecast to generate $429,437,216 in revenue, with the lowest revenue forecast at $0 and the highest revenue forecast at $4,863,111,671.